Legato Capital Management LLC cut its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 22.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 19,300 shares of the life sciences company’s stock after selling 5,700 shares during the quarter. Legato Capital Management LLC’s holdings in Illumina were worth $2,531,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Elyxium Wealth LLC bought a new stake in Illumina during the fourth quarter worth about $25,000. Creative Capital Management Investments LLC grew its holdings in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 120 shares during the period. Board of the Pension Protection Fund bought a new position in shares of Illumina during the fourth quarter valued at approximately $26,000. TD Waterhouse Canada Inc. purchased a new position in shares of Illumina during the fourth quarter valued at approximately $26,000. Finally, Laurel Wealth Advisors LLC purchased a new position in shares of Illumina during the fourth quarter valued at approximately $26,000. 89.42% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president directly owned 15,056 shares of the company’s stock, valued at $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 225,067 shares of Illumina stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $145.55, for a total value of $32,758,501.85. Following the completion of the sale, the director owned 3,604,441 shares of the company’s stock, valued at $524,626,387.55. The trade was a 5.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 330,160 shares of company stock worth $48,028,308. Corporate insiders own 2.90% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on Illumina
Illumina Price Performance
Shares of NASDAQ ILMN opened at $144.41 on Friday. Illumina, Inc. has a twelve month low of $78.55 and a twelve month high of $155.53. The firm has a market cap of $21.85 billion, a P/E ratio of 26.26, a PEG ratio of 2.40 and a beta of 1.42. The company has a 50 day moving average of $130.45 and a 200 day moving average of $130.91. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.
Illumina (NASDAQ:ILMN – Get Free Report) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s revenue was up 4.8% compared to the same quarter last year. During the same period last year, the business posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts expect that Illumina, Inc. will post 5.2 EPS for the current fiscal year.
About Illumina
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Stories
- Five stocks we like better than Illumina
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
